These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32351542)

  • 21. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
    AlFakeeh A; Brezden-Masley C
    Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Fang H; Huang D; Yang F; Guan X
    Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
    Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
    Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
    Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
    Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
    Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].
    Vanacker H; Bally O; Kassem L; Tredan O; Heudel P; Bachelot T
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S47-52. PubMed ID: 26118876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
    Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
    Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?
    Schettini F; Buono G; Trivedi MV; De Placido S; Arpino G; Giuliano M
    Breast Care (Basel); 2017 Oct; 12(5):290-294. PubMed ID: 29234247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer.
    Ballinger TJ; Meier JB; Jansen VM
    Front Oncol; 2018; 8():308. PubMed ID: 30148117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.
    Rugo HS; Vidula N; Ma C
    Am Soc Clin Oncol Educ Book; 2016; 35():e40-54. PubMed ID: 27249746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.
    O'Sullivan CC
    Int J Cancer Clin Res; 2015; 2(4):. PubMed ID: 26726315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers.
    Ngan RKC
    Ann Transl Med; 2018 Jul; 6(14):284. PubMed ID: 30105234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PI3K/Akt/mTOR inhibitors in breast cancer.
    Lee JJ; Loh K; Yap YS
    Cancer Biol Med; 2015 Dec; 12(4):342-54. PubMed ID: 26779371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.